Abstracts tagged "COVID-19"

Abstract Number: 1815 • ACR Convergence 2023
The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Preeti Dhanasekaran¹, Margaret Ma², Manjari Lahiri², Li Wearn Koh³, Stanley Angkodjojo⁴, Andrew Yu Keat Khor⁵, James Jiaqi Liu⁶, Stephanie Wong⁷ and Siaw Ing Yeo⁶, ¹National University of Singapore, Singapore, Singapore, ²National University Hospital, Singapore, Singapore, ³Tan Tock Seng Hospital, Braddell Heights, Singapore, ⁴Sengkang General Hospital / Singhealth, Singapore, Singapore, ⁵Changi General Hospital, Singapore, Singapore, ⁶Singapore General Hospital, Singapore, Singapore, ⁷Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: To determine the association of body mass index (BMI) with incident COVID-19 infection in patients with inflammatory arthritis (IA) using biologic disease-modifying anti-rheumatic drugs…
Abstract Number: 2159 • ACR Convergence 2023
Results of a 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic
Sofia Kuzkina¹, Eugen Feist², Nadezhda E. Banshchikova³, Anna A. Akimova³, Alexey E. Sizikov⁴, Arsen A. Mullagaliev³, Nadezhda A. Ilina⁴, Elena A. Letyagina³ and Maxim A. Korolev³, ¹R-Pharm, Moscow, Russia, ²Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ³Research Institute of Clinical and Experimental Lymphology – branch of Federal State Budget Scientific Institution « Federal Research Center “Institute of cytology and genetics of Siberian Branch of Russian Academy of Sciences", Novosibirsk, Russia, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia
Background/Purpose: The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases. This is primarily due to the…
Abstract Number: 0216 • ACR Convergence 2023
High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease
Rebecca Haberman¹, Rebecca Blank², Paula Rackoff², Gary Solomon³, Samrachana Adhikari¹, Natalie Azar⁴, Ramin Herati¹, Pamela Rosenthal⁵, Peter Izmirly⁶, Jonathan Samuels⁷, Brian Golden⁸, Soumya Reddy⁵, Mark Mulligan¹ and Jose Scher⁶, ¹NYU Grossman School of Medicine, New York, NY, ²New York University, New York, NY, ³NYU Langone School of Medicine, Hartsdale, NY, ⁴NYU Langone, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Langone, Rye Brook, NY, ⁸NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with immune-mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for COVID-19, yet IMID populations…
Abstract Number: 0446 • ACR Convergence 2023
Review of Rheumatoid Arthritis Treatment Landscape During the COVID-19 Pandemic
Rachel Connolly¹, MamTing Thoo², Elizabeth Baynton³ and Denise Baldock³, ¹Ipsos, New York, NY, ²Ipsos SDN BHD, Kuala Lumpur, Malaysia, ³Ipsos MORI UK, London, United Kingdom
Background/Purpose: During the COVID-19 pandemic, guidelines were amended with respect to the prescribing of biologic/tsDMARD usage to treat rheumatoid arthritis (RA). In addition, regulatory reviews…
Abstract Number: 1470 • ACR Convergence 2023
SARS-CoV-2 Antibody Formation After COVID-19 Vaccination in SLE Patients Treated with Belimumab: Single-Center Prospective Observational Study
Eun song Kang¹ and Yong-Gil Kim², ¹Korea University Ansan Hospital, Seoul, South Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Background/Purpose: Patients with systemic lupus erythematosus (SLE) should be more proactive with the administration of the COVID-19 vaccine, as their systemic conditions are prone to…
Abstract Number: 1822 • ACR Convergence 2023
The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA)
Laura Kangas¹, Lisa Wolf², Maya Beganovic³, Rachna Kapoor⁴, James Kidd⁴, Kate McCartan⁴, Kim Swank⁴ and Ida-Lina Diak⁴, ¹Food and Drug Administration, Bethesda, MD, ²Food and Drug Administration, Chevy Chase, MD, ³Food and Drug Administration, Chicago, IL, ⁴Food and Drug Administration, Silver Spring, MD
Background/Purpose: Baricitinib, a Janus kinase inhibitor, and tocilizumab, an interleukin-6 receptor antagonist, are two products first approved for the treatment of rheumatoid arthritis. Notably, these…
Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Tali Eviatar¹, Victoria Furer², Ilana Kaufman³, David levartovsky², Ofir Elalouf², Devy Zisman⁴, Tal Gazitt⁵, Amir Haddad⁴, Muna Elias⁶, Joy Feld⁷, Alexandra Balbir-Gurman⁸, Yolanda Braun Moscovici⁹, Sara Pel¹⁰, sharon Nevo¹¹, Daphna Paran² and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Ramat Gan, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Petah-Tikva, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶rheumatology unit, Haifa, Israel, ⁷Carmel and Zvulun Medical Centre, Haifa, Israel, ⁸Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁹Rambam Heath Care Campus, Haifa, Israel, ¹⁰Tel Aviv Medical Center, Modiin, Israel, ¹¹Tel Aviv Sourasky Medical Center, Givataim, Israel
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
Abstract Number: 0612 • ACR Convergence 2023
COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study
Kimberly Lakin¹, Jessica Gordon¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier², Richard Henry², Christopher Denton⁴, Luc Mouthon⁵, Robert Spiera⁶ and Brett Thombs², ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ³Radboud University, Nijmegen, Netherlands, ⁴University College London, London, United Kingdom, ⁵Hopital Cochin - Paris University, Paris, France, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: We previously surveyed individuals with systemic sclerosis (SSc) enrolled in Scleroderma Patient-centered Intervention Network (SPIN) Cohort between April-May 2021 to determine COVID-19 vaccination rates,…
Abstract Number: 1536 • ACR Convergence 2023
The Impact of COVID-19 Vaccination on ANCA Vasculitis Hospitalisations: A Perspective from Sydney Australia
Dane Turner¹, Grant Luxton¹, Kenneth Yong¹ and Anthony Sammel², ¹South East Sydney Local Health District, Sydney, Australia, ²Prince of Wales Hospital, Randwick, Australia
Background/Purpose: COVID-19 vaccination can trigger a range of inflammatory and auto-immune phenomena, potentially including AAV. There are several international case reports of de novo and…
Abstract Number: 1823 • ACR Convergence 2023
Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia
Paula David¹, Niv Ben-Shabbat², Or Hen¹, Howard Amital³, Abdulla watad⁴ and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²Department of Medicine 'B'. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³Sheba Medical Center - Tel Hashomer, Ramat Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Immunothrombosis is a critical pathological feature of fulminant COVID-19 pneumonia in which immunosuppression with common immunomodulatory agents such as corticosteroids, IL-6 receptor blockers, and…
Abstract Number: 2282 • ACR Convergence 2023
Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19
Arthur Mageau¹, Christel Gerardin², Kankoe Sallah², Jean-Francois Timsit¹, Thomas Papo¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France
Background/Purpose: The SARS-CoV2 pandemic reopened the unresolved question of whether and how a viral infection can trigger flares of immune-mediated inflammatory diseases such as systemic…
Abstract Number: 0218 • ACR Convergence 2023
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
Yumeko Kawano¹, Xiaosong Wang¹, Naomi Patel², Grace Qian¹, Emily Kowalski¹, Katarina Bade³, Kathleen Vanni¹, Accelerating Medicines Partnership (AMP): RA/SLE¹, Zachary Williams², Claire Cook², Shruthi Srivatsan², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…
Abstract Number: 0719 • ACR Convergence 2023
Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study
Lindsay Lally¹, Aliza Bloostein¹, Deanna Jannat-Khan¹ and Robert Spiera², ¹Hospital for Special Surgery, New York, NY, ²Hosptial for Special Surgery, New York, NY
Background/Purpose: Polymyalgia rheumatica (PMR) incidence peaks in individuals between 70 and 80 years of age; this same group is also at increased risk of complications…
Abstract Number: 1609 • ACR Convergence 2023
Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study
Danilo Perretta¹, Daniele Mauro¹, flavia riccio¹, valentina marino¹, emma scoppetta², Francesco ciccia¹ and rosella tirri¹, ¹University of Campania - Luigi Vanvitelli, Naples, Italy, ²University of Salerno, Salerno, Italy
Background/Purpose: SARS-CoV-2 infection has been increasingly recognized for its potential neurological manifestations. Fibromyalgia (FM) patients, who already experience neuropathic pain, may be particularly vulnerable to…

« Previous Page
1
…
7
8
9
10
11
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].